Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Edwards Lifesciences (EW) PT Raised to $186 at Raymond James
February 1, 2019 7:47 AM ESTRaymond James analyst Jayson Bedford raised the price target on Edwards Lifesciences (NYSE: EW) to $186.00 (from $175.00) while maintaining a Outperform rating.
... MoreEdwards Lifesciences (EW) PT Raised to $175 at UBS
February 1, 2019 7:15 AM ESTUBS analyst Matthew Taylor raised the price target on Edwards Lifesciences (NYSE: EW) to $175.00 (from $165.00) while maintaining a Neutral rating.
... MoreEdwards Lifesciences (EW) PT Raised to $182 at RBC Capital
February 1, 2019 6:42 AM ESTRBC Capital analyst Glenn Novarro raised the price target on Edwards Lifesciences (NYSE: EW) to $182.00 (from $175.00) while maintaining a Outperform rating.
Novarro commented, "Revenue guidance for 1Q19, implying high-single-digit CC growth at the midpoint, adequately captures competitive dynamics in the TAVR market.... More
Edwards Lifesciences (EW) Reports In-Line Q4 EPS, Q1 EPS Guidance Comes in Light
January 31, 2019 4:19 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $1.17, in-line with the analyst estimate of $1.17. Revenue for the quarter came in at $978 million versus the consensus estimate of $975.92 million.
GUIDANCE:
Edwards Lifesciences sees Q1 2019 EPS of $1.15-$1.25, versus the consensus of $1.30.... More
